Schott Pharma has announced a change in leadership: long-standing CEO Andreas Reisse will retire as planned in April 2026. His successor will be Christian Mias, currently Executive Vice President of the Electronic Packaging business unit at Schott. The Supervisory Board has appointed him as the new CEO with effect from 1 May 2026.
After a transition phase, which Reisse will actively support, Mias will ensure continuity in the company's management. Mias, who holds a doctorate in industrial engineering, has worked for the Schott Group for 18 years in various management positions and has extensive international experience from Europe, the USA and Brazil. He has already gained important insights into the pharmaceutical industry at Schott Tubing, which manufactures precursors for Schott Pharma. Mias is regarded as a manager with a strategic focus and operational experience in process optimisation and profit improvement.
Supervisory Board honours Reisse and focuses on growth with Mias
Peter Goldschmidt, Chairman of the Supervisory Board of Schott Pharma AG & Co. KGaA, emphasised the importance of the personnel decision. He referred to Mias„ “proven success" within the Group and his integrative management style. According to Goldschmidt, Mias, together with CFO Reinhard Mayer, will continue to drive profitable growth and strengthen the company's international position.
Reisse, who has worked for Schott since 1987 and headed the Pharmaceutical Systems division - now Schott Pharma - since 2010, will retire after reaching the statutory age limit. The Supervisory Board particularly recognised his role in the further development of the company into a leading global supplier of pharmaceutical packaging and application systems. This also includes the successful IPO in 2023.
Source: Schott Pharma
